Resmed (RMD) Non-Current Deffered Revenue (2010 - 2026)

Resmed (RMD) has 17 years of Non-Current Deffered Revenue data on file, last reported at $163.1 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 7.98% year-over-year to $163.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.1 million (up 7.98% YoY) and the FY2025 annual result came in at $156.8 million, up 14.17% from the prior year.
• Non-Current Deffered Revenue advanced to $163.1 million in Q1 2026, from $159.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $163.1 million in Q1 2026 to a low of $94.1 million in Q1 2022.
• A 5-year average of $130.4 million and a median of $132.0 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue gained 4.33% — and 2023, when it rose 24.86%.
• Tracing RMD's Non-Current Deffered Revenue over 5 years: stood at $102.8 million in 2022, then climbed by 23.94% to $127.4 million in 2023, then advanced by 14.99% to $146.5 million in 2024, then grew by 9.06% to $159.8 million in 2025, then climbed by 2.1% to $163.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $163.1 million (Q1 2026), $159.8 million (Q4 2025), and $159.4 million (Q3 2025), per Business Quant data.